| Date & Time | 12 February 2026 |
|---|---|
| Location | Online Event |
Building on EATRIS’ commitment to advancing innovative, predictive, and patient-centred translational science, we are pleased to announce a Digital Symposium dedicated to New Approach Methodologies (NAMs) and their transformative potential for medicines development and repurposing.
This 3-hour online symposium will take place on 12 February 2026 and will bring together members of the EATRIS Small Molecules Platform and broader community to explore the latest advances in predictive translational models and discuss how NAMs canimprove reproducibility, regulatory alignment, and patient impact.
Background
High-quality, robust, and predictive translational models are essential for improving the success of drug discovery, development, and repurposing. As regulatory agencies increasingly support the adoption of more predictive and human-relevant systems – collectively referred to as New Approach Methodologies (NAMs) – the translational research community is uniquely positioned to lead this transformation.
NAMs encompass advanced organoids, 3D cultures, iPSC-derived models, microphysiological systems, phenotypic screening, and may include AI-enabled approaches that provide higher translational value than conventional animal models. These platforms offer new opportunities to enhance clinical relevance, reduce attrition rates, and streamline decision-making across the R&D pipeline.
This symposium will explore how EATRIS members are developing and implementing NAMs, and you are invited to include case studies, share success stories, and lessons learned from regulatory engagement and technology adoption. Participants will discuss the scientific and operational challenges of deploying NAMs as robust, reproducible, and compliant tools to accelerate medicine development and repurposing.
Discussion Topics
- How can NAMs improve prediction of clinical outcomes compared to animal models?
- Which NAMs are emerging as promising tools across discovery, safety, and efficacy assessment?
- How can AI support the design, interpretation, and integration of NAM data?
- What are best practices for ensuring regulatory acceptance and standardisation?
- How can EATRIS members share experiences—successes and failures—to accelerate adoption?
Register and Get Involved
Background reads:
- Editorial by E. von Keutz, “New Approach Methodologies in Drug Development,” Drug Disc. Today (2025) (DOI:10.1016/j.drudis.2025.104475)
- F. Pistollato et al. “Leveraging innovative research tools to meet public health challenges: a BioMed21workshop report”, NAM Journal (2025) https://doi.org/10.1016/j.namjnl.2025.100023
- A.S. Robertson et al. “Accelerating adoption of new approach methodologies in regulatory decision making: an industry perspective” Nat. Rev. Drug. Disc. (2025) https://doi.org/10.1038/d41573-025-00038-6
